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Abstract
This chapter provides a brief overview of diabetes prevalence, the associated complica-
tions, diabetes-related mortality and management strategies to set the context for dis-
cussing palliative and end-of-life care. This chapter highlights: (1) The increasing global 
focus on palliative and end-of life-care; (2) The relationship among health trajectories, 
function and palliative and end-of-life care; (3) The imperative to plan care with the indi-
vidual to achieve personalised care that meets the individual’s goals, preferences, val-
ues and spiritual needs across the various health trajectories; (4) The need to proactively 
plan for the transition to palliative and end-of-life care when appropriate and while the 
individual can make informed decisions. Proactively planning for changing care needs 
is more likely to achieve care consistent with the individual’s goals, values and prefer-
ences; (5) The key role of family carers and the effect of caring on carers’ health; (6) The 
importance of having timely, meaningful conversations about palliative and end-of-life 
care with people with diabetes and their families; and (7) The imperative to ameliorate 
suffering, optimise quality of life and personalising care.
Keywords: diabetes, health trajectories, palliative, end-of-life, communication
1. Introduction
1.1. Diabetes: a significant issue also in palliative care setting
Chronic diseases are the leading cause of death globally [1]. Diabetes is the most prevalent 
chronic disease affecting 422 million people worldwide [2]. Diabetes is linked to 3.7 million 
deaths per year [2] and is often associated with other chronic diseases, especially hyperten-
sion, cardiovascular disease and renal disease, as well as some forms of cancer. Globally, one 
person with diabetes dies every six seconds [3].
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Most chronic disease-related deaths occur in older age and are associated with potentially 
remediable physical, emotional and spiritual suffering [4].Relief from suffering is more likely 
to be achieved if palliative care is initiated early [5]. In addition, early initiation of palliative 
care leads to cost savings [4]. Significantly, outcomes for people who receive early palliative 
care are better than those who receive ‘usual’ care [6]. Consequently, the management of 
diabetes and its complications is a significant issue to be addressed early in the course of the 
disease and also in palliative care settings.
People with diabetes are living longer; but diabetes is associated with 8–11% lower 5–10 
years survival rates [7]. However, older people with diabetes are a heterogeneous popula-
tion and there are different types of risks within the population. Several interrelated factors 
affect survival: duration of diabetes >12 years, poor glycaemic control, multiple comorbidities 
(comorbid load), especially cardiovascular disease and heart failure, end stage renal failure, 
advanced foot disease and frailty.
Polypharmacy confers an increased mortality risk for people with diabetes through the 
interactions among medicines and individual medicine side effects. For example, thiazoli-
dinedione glucose lowering medicines are linked to heart failure and other cardiovascular 
mortality [8]. Insulin and sulphonylureas are linked to adverse outcomes in older people 
with diabetes and mortality [9, 10]. Currie et al. [9] described mortality hazard between 10 
and 34% for these medicines in combination with metformin and even higher levels when 
they were used as monotherapy. Glycaemic control is important with good control, HbA1c, 
<7% (53 mmol/mol) conferring benefits. However, hypoglycaemia is associated with risk of 
cardiac changes and death, especially in older people and can occur when HbA1c is high as 
well as low [11].
These risks highlight the importance of identifying and managing the factors that affect mor-
tality as early as possible in the health trajectory, see Section 6. Individually and collectively, 
they are associated with increased costs, unnecessary interventions, including in the late 
stages of life, and consequent physical and mental suffering for people with diabetes and 
families. They also need to be considered and managed in palliative care settings.
2. Managing diabetes
Diabetes management requires interdisciplinary team care. Collaborative, respectful interdis-
ciplinary care predicated on effective communication is essential when palliative and end-
of-life care is indicated. Diabetes education is regarded as the cornerstone of management 
and is essential to enable the individual to undertake self-care such as blood glucose moni-
toring, managing medicines and attending health professional appointments to achieve good 
outcomes. Education about palliative care options and planning for end-of-life care are not 
currently regarded as core aspects of diabetes education. However, these issues should be 
discussed as the person’s health and functional status (trajectory) changes.
Eating a healthy diet, regular physical activity/exercise and managing stress (lifestyle factors) 
are key management strategies for all types of diabetes and for people of all ages, including 
Highlights on Several Underestimated Topics in Palliative Care110
when glucose lowering medicines (GLM) and other medicines are required [12]. Healthy active 
lifestyle also helps protect telomeres and overall health [13].
The broad aim of diabetes management is to keep the blood glucose and HbA1c (an indicator 
of the average blood glucose level over 3 months) as close to the normal range as possible to 
prevent or manage long-term diabetes complications. Such complications are associated with 
reduced life expectancy. However, the blood glucose and HbA1c range must be safe for the indi-
vidual depending on their functional category, disease trajectory and life expectancy [12, 15].
The risk of severe hypoglycaemia increases, if HbA1c and blood glucose ranges are near or 
lower than normal in people with multiple comorbidities, longer duration of diabetes and 
those on insulin/sulphonylureas [11]. Hypoglycaemia is associated with other risks such as 
falls. Hyperglycaemia can also contribute to falls cognitive changes and delirium. Example 
HbA1c and blood glucose ranges are as follows:
2.1. HbA1c
• In healthy people with short duration of diabetes, no cardiovascular disease, and no severe 
hypoglycaemia, the HbA1c range is 6.5–7.0% (48–53 mmol/mol). The focus is on preventing 
complications [3, 14, 15].
• In frail older people with complication’s and comorbidities, limited life expectancy and 
those at the end-of-life, the HbA1c range is 8–8.5% (64–69 mmol/mol). The focus is on man-
aging existing complications to promote safety (palliative approach) [3, 14, 15].
2.2. Blood glucose
• Healthy people with type 2 diabetes (T2DM): fasting 6–8, postprandial 6–10 mmol/L [15].
• Frail older people, those with dementia and those with high hypoglycaemia risk on GLMs 
6–11 mmol/L [15].
Thus, the management focus and the metabolic parameters used to determine the effective-
ness of management strategies often need to change as function and the health trajectory 
change [16, 17]. Palliative care is a valuable care option, however, many people who would 
benefit from palliative care to manage symptoms and reduce suffering are not offered such 
care because health professionals underestimate the problem and are often reluctant to dis-
cuss the issue or to give ‘bad news’ [17]. People with life limiting illnesses should not be 
excluded from potentially beneficial treatment.
Palliative care can be used for seriously ill surgical patients, and preoperative screening for 
frailty can reduce 180 days mortality [18]. Likewise, a systematic review of 25 paper involving 
8575 patients and 22 different interventions suggests preoperative decision-making concern-
ing palliative care can improve communication, symptom management and reduce use of 
health care resources and costs [19]. More research is required to substantiate these findings 
due to methodological flaws and differences and small sample sizes in many of the papers 
included in the review.
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3. Glucose lowering medicines
The main types of GLMs are shown in Table 1.
Medicines, including GLMs, play a key role in diabetes management in all health trajecto-
ries. Medicines confer significant benefits, but they are also associated with adverse events, 
including in palliative care settings. Ageing and diabetes-related pathophysiological changes 
and their subsequent risks significantly affect medicine safety and medicine choices and 
increase the risk of medicine-related adverse events [20]. As people with diabetes grow older, 
or develop dementia, they have difficulty managing their medicines and rely on other people 
to help them manage their medicines and other diabetes self-care and activities of daily living. 
Difficulty managing medicines is one reason for admission to a care home [20].
Key changes that affect medicine action, effectiveness and safety include:
• cardiovascular changes, which affect medicines distribution
• liver changes, which affects medicine metabolism
• renal disease, which affects excretion
• gastrointestinal changes that affect absorption of oral medicines
• changes in the counter-regulatory response to hypoglycaemia due to reduced production 
of glucagon and autonomic neuropathy, which cause hypoglycaemic unawareness
• cognitive and sensory changes, which affects independence and medicine adherence.
Polypharmacy is common in people with diabetes, especially people with type 2 diabetes who 
have comorbidities. Polypharmacy might be indicated to manage symptoms and comorbidities, 
but it is important to use non-medicine options where possible and to ensure polypharmacy is 
‘thoughtful’. That is, where possible medicines should be stopped before starting another medi-
cine and not commencing medicines whose benefits take longer than the person’s life expectancy 
[20]. The risks and benefits of each medicine must be considered individually, and in the context 
of the whole medicine regimen, and the individual’s goals, preferences and values [21, 22].
Diabetogenic medicines such as corticosteroids, antipsychotics and thiazide diuretics can contrib-
ute to hyperglycaemia and induce diabetes in previously undiagnosed older people [3, 15]. High 
dose corticosteroids are often used in cancer to manage symptoms, cachexia and poor appetite.
3.1. Hypoglycaemia
Changes in pancreatic alpha cells with increasing duration of diabetes and advancing age 
affects glucagon production, which reduces the individual’s ability to mount an effective 
counter-regulatory response to hypoglycaemia [22–24]. In addition, autonomic and sen-
sory changes affect the individual’s ability to recognise the usual hypoglycaemic autonomic 
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Type of medicine Main mode of action Main side effects
Oral GLMs
Metformin Reduces hepatic glucose output. Gastrointestinal (GIT) problems such 
as bloating and flatulence in the early 
days.
GIT problems less likely with slow 
release dose forms (these should not be 
crushed).
Rarely lactic acidosis—contraindicated 
in significant renal failure.
Long-term use might lead to vitamin B12 
deficiency and lead to anaemia and its 
consequences.
Sulphonylureas Binds to the beta cell receptor and 
triggers insulin release independent 
of glucose.
Hypoglycaemia.
Weight gain.
DPP-4 inhibitors Improve beta cell function and 
insulin secretion. Reduces gastric 
emptying and postprandial blood 
glucose.
GIT problems.
Nasopharyngitis.
Heart failure in people with or at risk of 
cardiovascular disease.
Thiazolidinediones (TZD) Sensitise tissues to insulin. Weight gain.
Fluid retention.
Heart failure.
Risk of non-axial fracture in women
Alpha-glucosidase inhibitor Slows carbohydrate absorption 
from the intestines and reduces 
postprandial blood glucose.
GIT problems especially bloating and 
flatulence.
Sodium-glucose cotransporter-2 
(SGLT-2)
Inhibit the SGLT-2 transporter 
exchange sodium and glucose in the 
kidney and glucose is excreted in the 
urine.
Reduces systolic blood pressure and 
cardiovascular risk.
Dehydration.
Dizziness.
Risk of genitourinary infections.
Older people risk of electrolyte changes 
and hyperosmolar states.
Not use with loop diuretics.
Injectable GLMs
GLP-1 Weight loss
GIT problems especially nausea and 
vomiting
Insulin*
Short, rapid, intermediate and 
long acting analogues
Premixed
Lower blood glucose Hypoglycaemia
Notes: *Injecting repeatedly into the same site can cause lipodystrophy and lipoatrophy. Injecting in lipodystrophy/
atrophy tissue or using incorrect injection technique or needle size can affect insulin action and effectiveness and lead 
to glucose variability [51].
Combinations of some types of oral GLMs and of the different types of insulin are available.
Table 1. Classes of glucose lowering medicines, main mode of action and main side effects.
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warning symptoms (sweating, trembling and palpitations) and put them at significant risk of 
severe hypoglycaemia requiring hospital admission, and cardiovascular complications [25].
A severe hypoglycaemia is associated with poor prognosis, leads to cognitive changes, coma, 
falls and injuries such as fractures, cognitive changes, acute coronary syndrome, recurrent 
hypoglycaemia, admission to hospital and sudden death [22, 23]. Hypoglycaemia affects 
age-related cognitive function due to changes in the counter-regulatory response to hypo-
glycaemia and the delivery of ‘fuel’ to the brain. Executive function is affected and reduces 
the individual’s ability to recognise, problem-solve, make decisions, including about treating 
their hypoglycaemia [26] and is associated with dementia in the long term [27]. In addition, 
hypoglycaemia engenders fear, reduces quality of life (QOL) of the individual and family 
caregivers [28].
3.2. Hyperglycaemia
Hyperglycaemia is not a benign condition. It is an underlying cause of complications that 
affect functional status and life expectancy [3, 15]. It causes unpleasant symptoms and other 
metabolic changes such as incontinence, dehydration, triggers inflammatory processes, 
increases risk of intercurrent infections, weight loss and affects cognitive function. Some of 
these processes can lead to ketoacidosis (DKA) in type 1 diabetes (T1DM) and hyperglycae-
mia hyperosmolar states (HHS) in T2DM [3, 14, 15].
4. Palliative care
Palliative care was traditionally used to refer to care of people at the end-of-life. Definitions of 
palliative, end-of-life and terminal care are shown in Table 2. It is important to note that the 
definition of palliative care changed over 6 years ago to encompass chronic diseases that have 
a longer trajectory to end-of-life [29]. The definition was changed to reflect the association 
among chronic disease, suffering and life expectancy, and the fact that the chronic disease and 
frailty trajectories to death are less predictable than and different from the cancer trajectory. 
Health trajectories are described in Section 6.
As indicated, palliative care improves function and QOL and reduces unwanted hospital 
admissions and aggressive end-of-life care. It can be delivered in various settings such as in 
individual’s homes, hospital, aged care homes and hospices. Palliative care can be integrated 
with usual diabetes care including at diagnosis, or can replace usual care.
Palliative care is associated with improved outcomes if it is implemented early; but most 
people are not referred to palliative care services until last few weeks of life [29, 30] and are 
often admitted to and die in intensive care units, despite meeting Gold Standards Framework 
(GSF) criteria [31]. Significantly, older people often meet medical emergency team (MET) cri-
teria before they are discharged from hospital and often represent 30 days of discharge or 
sooner [32].
MET criteria refer to vital signs such as blood pressure, respiration and heart rate and rhythm 
that are monitored to detect change to enable treatment to be implemented to prevent a medical 
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emergency. Worryingly, 25% of people are discharged on the same day they have a MET call [33], 
and 30% of people aged 70 and 50% of those aged 80 and older leave hospital more disabled 
then when they were admitted. Recognising and responding to deterioration is essential [34] to 
treat remedial deterioration as soon as possible. Blood glucose monitoring can be a useful tool 
to detect deterioration associated with hypo- and hyperglycaemia and implement treatment 
before preventable conditions such as DKA and HHS. That is, the health trajectory and life 
expectancy can change during and after a hospital admission.
4.1. Goals of palliative care
The main goals of palliative care are to:
• Improve and maintain function to support independence and QOL.
• Achieve their life goals.
• Remain comfortable and free of pain and distressing symptoms.
• Achieve a dignified death in their place of choice.
• Address their spiritual, cultural and religious needs.
These goals also apply to individuals with diabetes [3, 35, 36]. They highlight the importance of 
discussing life and care goals, values and preferences with people with diabetes and ensuring 
Palliative care Palliative care is predicated on the fact that dying is a 
normal process. It focuses on improving quality of life 
by relieving suffering, promoting comfort and managing 
symptoms through comprehensive assessments and 
personalising care by engaging with the individual and 
family carers. Palliative care can be integrated with usual 
diabetes care at any stage in the disease trajectory. Most 
benefits accrue when palliative care is introduced early. 
It emphasises the importance of counselling patients and 
families, supporting patients to understand the change in 
the focus of care and helping them make decisions about 
their treatment and goals of care, documenting their end-
of-life care preferences and care coordination.
Advance care planning The process patients, family members or surrogate 
decision-makers and health professionals anticipate, 
discuss, document and communicate treatment options 
as the health status changes. Advance care plans help 
health professionals make ‘in the moment decisions’, 
which can be emotionally confronting, especially when 
there is conflict within the family.
End-of-life care End-of-life care refers care for likely to die in the 
following 12 months. It includes imminent death in a few 
hours or days and progressive incurable life-threatening 
illnesses such as diabetes.
Terminal care Last few days or hours of life.
Table 2. Definitions of palliative care, advance care planning and end-of-life care and terminal care [29, 35, 36].
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they are documented and communicated to the family and the individual’s other clinicians. 
Clinicians need to accept that the individual may have different views from their own, and 
often from their family. In addition, people can change their care preferences over time; there-
fore, clinicians should ask about any changes for time-to-time such as during annual health 
reviews, preoperative assessments and changes in health status.
It is also important to provide support for families and other caregivers, including after the 
death of a loved one when they are particularly vulnerable to acute cardiovascular events, 
infection and depression [3, 38, 39].
4.2. Health trajectories
The complex changing nature of diabetes and prognostic uncertainty makes it difficult to pre-
dict when an individual with diabetes would benefit from palliative care. Understanding their 
functional status and health trajectory can enable health professionals to discuss future care 
including the option of palliative care and to commence planning for the end-of-life. The follow-
ing health trajectories are a useful framework for monitoring current and changing health status 
and care needs and to plan care with people with diabetes to meet changing needs [40, 41].
Unintentional injuries in older people, especially falls, often lead to death and can occur in 
any health trajectory.
1. Trajectory 1: Health trajectory where the person is independent, and has none or few 
complications when the focus is on maintaining health and preventing complications by 
striving for normoglycaemia (tight glycaemic control). However, death can be sudden in 
diabetes due to hypoglycaemia or silent myocardial infarction.
2. Trajectory 2: Sometimes called the cancer trajectory. There is a steady reasonably predict-
able decline in physical health over time (weeks, months or years). However, some cancers 
are curable and people may survive for many years and are referred to as cancer survivors. 
That is, they enter another health trajectory.
3. Trajectory 3: It is associated with long-term functional decline and intermittent periods of 
deterioration (unstable diabetes, e.g., due to intercurrent illness) that can be serious and 
require admission to hospital and/or intensive care unit (ICU). The individual usually re-
covers, but each deterioration results in further decline and can result in death. The time 
of death is unpredictable. Older people admitted to ICU are likely to die and may derive 
more benefit from palliative care, which avoids unnecessary life-prolonging treatment. 
Generally, QOL and pain management are more important to people with limited life ex-
pectancy than prolonging life.
4. Trajectory 4: People who do not have cancer or chronic diseases that cause organ damage/
failure are likely to die at an older age from dementia or generalised frailty that involves 
multiple body systems after ‘prolonged dwindling’.
Physical, psychological and spiritual needs differ among people with diabetes and their fami-
lies and among and within the trajectories. Therefore, palliative and end-of-life care plans 
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should be developed sensitively and reviewed regularly to ensure they reflect the preferences 
of the individual [35, 40, 42]. Cultural and religious beliefs and traditions about health/ill 
health, death and dying must be considered and respected, including care of the body after 
death. Table 3 shows some assessment and screening tools that can be used to monitor the 
individual’s trajectory.
Malnutrition, deficient calorie, vitamin, mineral, protein, water intake, contributes to 
frailty and ‘failure to thrive’ in older people described in trajectory 4 [43]. Failure to thrive 
is associated with weight loss, often dehydration, skin fragility, osteoporosis, depres-
sion, immune system dysfunction, low cholesterol and functional decline [43]. Diabetes 
complications affect the individual’s ability to thrive, as do some medicines. It is present 
in 5–35% of community dwelling older Americans, 25–40% of older people in aged care 
homes and increases the risk of morbidity and mortality. Palliative can be very valuable 
in such people.
It is generally difficult to precisely predict when an individual will die. Prognosis prediction 
models and their clinical utility in palliative care are addressed in a dedicated chapter of this 
book.
Some general indicators of poor prognosis are described in the Gold Standards Framework 
(GSF) [31] and can also inform care decisions, for example:
• Sarcopenia and frailty.
• Hospital admissions—increased risk of death in people >65 years with mulitmorbidities 
and heart failure.
• Sentinel events such as a fall, bereavement, and admission to and aged care home.
• Serum albumin <2.5 g/dL.
• Weight loss >10% in the preceding 6 months, although some experts indicate weight loss 
>5% over 6 months should be investigated.
Another useful prognostic indicator is the ‘surprise question’: would I be surprised if this per-
son died in the next 12 months? If the answer is ‘no, I would not be surprised’, it is time to dis-
cuss and document palliative and end-of-life care, if that has not already been done [31, 41]. 
Documented palliative/end-of-life care plans should be reviewed. If the answer is ‘yes’ it 
could be time to begin initiating health professional and family case conferences.
Physical, psychological and spiritual needs differ among people with diabetes and their 
families and among and within the trajectories. As indicated, palliative and end-of-life 
care plans should be reviewed regularly to ensure they reflect the preferences of the indi-
vidual. Cultural and religious beliefs and traditions about health/ill health, death and 
dying must be considered and respected including care of the body after death. The risk 
of developing many diseases increase with age, including diabetes, dementia and some 
forms of cancer; 80% of cancers occur after age 60 [44]. Some cancers and type 2 diabetes 
are associated with obesity [45]. Thus, it is reasonable to expect the health trajectory to 
change over time.
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Tool Comments
The surprise question Would I be surprised if this person 
died within 12 months?
Ask any time health changes.
Gold Standard Framework (GSF) prognostic indicator 
guidance
General indicators of decline/deterioration and the 
increasing need or choice for no further active care.
Includes the surprise question.
Cognitive assessment toolkit
Mini-mental examination
Assess cognitive function.
Supportive and palliative care indicators tool (SPICT) Identify people at risk of deteriorating and dying.
Palliative care necessities CCOMS-ICO (NECPAL) Identify people in need of palliative care.
RADboud indicators for palliative care needs (RADPAC) Identify indicators of palliative care needs.
Charlson comorbidity index (CCI) Designed to estimate 1–10 years mortality in longitudinal 
studies but is not a valid prognostic indicator for short 
term outcomes.
Clinical frailty scale Determine frailty and function.
Karnofsky performance status scale Quality of life across the spectrum of health from well to 
terminal.
Barthel index Assesses capacity to perform basic activities of daily 
living.
Confusion assessment method (CAM) Determine presence of confusion.
Weight, body mass index, food records, and nutrition 
assessment tools
Monitor nutrition status and related risk of malnutrition.
Hypoglycaemia risk assessment tool Determine risk of hypoglycaemia. Available in the 
McKellar Guidelines www.adma.org.au/…/133-the-
mckellar-guidelines-for-managing-older-people-with-
diabetes-in-residential-and-other-care-settings_9dec2013
Diabetes-specific medicine-related adverse risk 
assessment tool
Determine risk of medicine-related adverse events. 
Available in the McKellar Guidelines
Medicine-related tools, e.g., Beers and STOPP/START Used when prescribing medicines, when new symptoms 
develop and to undertake regular medicine reviews.
When any new medicines is commenced and new 
symptoms develop especially in older people.
Absolute cardiovascular risk benefit calculator Estimate cardiovascular risk including when prescribing 
medicines.
Fracture risk assessment tool (FRAX) Estimate risk of fracture including when frail and when 
prescribing medicines.
Acute physiology and chronic disease evaluation 
(APACHE) and its variants
Designed to measure severity of disease in adults and 
used to predict in-hospital death and risk-adjusted length 
of stay in ICU.
Indicate risk of death in patient groups rather than 
specific individuals and depend on laboratory data.
Table 3. Some useful assessment/screening tools can be used in any health trajectory.
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5. Personalised palliative, end-of-life care and advance care planning
It is essential to actively involve people in decisions about their care goals, targets and plan 
including commencing and stopping medicines and other treatments. Involving people in 
care decisions can be challenging for many health professionals, especially when it concerns 
emotive issues such as palliative and end-of-life care. Well-designed training courses can 
improve health professional communication skills [32]. Health professionals find it difficult to 
resolve the dilemma among ‘truth telling’, instilling hope, and respecting people’s autonomy. 
Truth telling often means delivering ‘bad news’ and is stressful. Thus, despite the global trend 
towards ‘truth telling’, non-disclosure is still an issue [29, 45].
People with a life-threatening illness (and their families) often ask ‘how long have I got?’ 
Inherent in that question is recognition that they have a life-threatening illness and need some 
guidance about the likely health trajectory (what will happen?), so they can complete ‘unfin-
ished business and get their house in order’. They may not initiate discussion about the issue, 
often because they do not want to upset family, friends or their health professionals. In most 
cases, people are not concerned so much about dying, as they are of suffering, and having 
loved ones witness their suffering [38, 46].
Most people want to die at home and die with dignity [29, 30]. Several resources and decision 
aids are available to help people with diabetes and health professionals make care decision by 
helping them decide an individual’s personal risks and leads to the appropriate use of elective 
procedures [47]. Some useful resources are listed after the reference list.
5.1. Advance care planning
Various countries have different legislative and other procedures guiding advance care planning. 
Such planning involves shared responsibility among health professionals, the individual and their 
families. The aim is to identify the individual’s values, preferences and goals and communicate 
them to relevant services and relevant others so the plan can be implemented when indicated.
Research shows people with cancer and dementia have a better end-of-life quality than those 
with end stage renal disease, cardiopulmonary failure and frailty [29, 30]. Some possible rea-
sons include early initiation of palliative care, documented advance care plans, ‘not for resus-
citation orders’, and fewer admissions to ICU [32, 47]. These findings suggest it is imperative 
that other disease processes ensure palliative and end-of-life care planning are included in 
clinical management guidelines.
Key information to discuss and document includes preferences concerning:
• Resuscitation
• Airway support
• Enteral nutrition and fluids
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• MET calls if they are admitted to hospital
• Pain management
• Diabetes self-care such as blood glucose monitoring and GLMs
• Other important end-of-life planning includes religious, spiritual and cultural issues sur-
rounding end-of-life care, making a will, funeral planning and designating surrogate deci-
sion-makers/power of attorney.
6. Good communication
Communication is central to effective palliative care planning. Listening, effective use of silence 
and using appropriate probing and clarifying questions are key clinician skills [46]. A variety 
of communication strategies have been designed to enhance health professional and people 
with diabetes capacity to discuss these emotive issues in a timely and sensitive manner and 
help reduce uncertainty. However, decisions about treatment options are increasingly com-
plex in an age where advanced technology and treatments promise the hope of extending life.
Initiating discussion about end-of-life care earlier and in a planned manner enables people to 
make more informed choices when they are not under physical or mental stress and achieve 
better outcomes. People who discuss their palliative and end-of-life care needs are more likely 
to receive care consistent with those preferences [6, 29, 30]. Such discussion includes clarify-
ing the individual’s goals and their concept of what a ‘good death’ means to them. Health 
professionals need to have the relevant skills to communicate about these issues.
7. Family carers
Family carers, often a spouse, play a significant role supporting and caring for people with 
diabetes. They often have health problems themselves and are at high risk of unexpected 
morbidity and mortality after the death of a loved one, especially if the death is unexpected 
and not planned for [37, 38]. Caring is hard work and often causes stress that affects sleep, 
immunity and wellbeing and mobilises inflammatory processes and haemodynamic changes 
that predispose them to dying [37]. The family carer can neglect their own health care such as 
taking medicines to perform the caring role. Therefore, carers also need a care plan and their 
health needs to be monitored. Keeping carers informed and included in case conferences and 
care decision can reduce stress.
A significant cause of family stress the uncertainties associated with dying. These include under-
taking diabetes management tasks such as blood glucose monitoring and injecting insulin and 
understanding when their loved one is actively dying [46]. Family are often reluctant to support 
loved ones die at home because of these uncertainties and the responsibility involved. Ensuring 
these issues are included in family discussions can help relieve stress. Significantly, carer wellbe-
ing affects the experiences of the person they provide care for. The latter are likely to report poor 
quality of life if their carer has depression [47]. Thus, carers can be ‘invisible’ or ‘hidden’ patients.
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8. What do people with diabetes think?
People with diabetes and their health professionals face many complex decisions where there 
is no right or wrong answer when considering palliative and end-of-life care. Prognostic 
uncertainty, competing priorities and weighing benefits and risks overall and the positive 
and negative outcomes of treatment complicate decision-making [30]. Such decisions can be 
particularly challenging with respect to managing diabetes when the focus on tight blood 
glucose control no longer confers benefit and changes to focusing on safety comfort and qual-
ity of life, especially given there are no large observational or randomised controlled trials to 
support many care recommendations [40].
We interviewed people with diabetes receiving palliative care for a range of diagnoses, their 
family carers (mostly spouses) and palliative care health professionals when we developed 
Guidelines for Managing Diabetes at the End of Life [35]. Our research suggests people with 
diabetes and families regard blood glucose testing as an important guide to detecting hypo- 
and hyperglycaemia, both of which compromise comfort [47, 48]. It is also a reassuringly 
familiar routine in a sometimes rapidly changing world.
People with diabetes indicated health professionals do not pay enough attention to their dia-
betes, do not understand the physical and psychological impact of hypo- and hyperglycae-
mia and the relentless self-care required to manage diabetes and do not respect their lifetime 
of accumulating diabetes knowledge and solving diabetes care problems. Generally, they 
wanted blood glucose monitoring continued until the final stages of dying because ‘it helps 
sort out the causes of things like confusion and pain’ [47]. They also wanted to continue tak-
ing their GLMs until the terminal stage to manage hyperglycaemia, which they stated caused 
confusion, frequency and tiredness, what affected their comfort and quality of life.
Carers were interviewed separately and reported similar views. They also reported they wor-
ried about having to undertake diabetes tasks such as blood glucose testing and administer-
ing insulin because they had not received education about these tasks and worried that they 
might accidently give the wrong insulin dose and hasten death [47, 48].
Our earlier research indicated health professionals reported dilemmas deciding when ‘is the 
right time, to stop blood glucose monitoring and felt finger pricking caused discomfort. They 
felt ‘there was a tension between avoiding discomfort and performing useful investigations’ 
[49]. This study was the impetus for developing the Guidelines for Managing Diabetes at the 
End of Life [35], which as currently under review.
9. Summary
Proactively planning for palliative and end-of-life care can improve comfort and other out-
comes for people with diabetes, especially in older age, and their families. Planning for the 
end-of-life is a shared responsibility between health professionals, people with diabetes and 
often family carers and reduces decisional conflict when health deteriorates. It is essential to 
understand people’s goals, values and preferences and to personalise care. It is important 
to consider culture and religion and proactively monitor the individual’s and their families’ 
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health status. Palliative care aims to promote comfort and alleviate suffering (see Table 2) 
It can be initiated at any time in the diabetes trajectory: early initiation results in better out-
comes. General palliative and end-of-life care/guidelines discussed in other chapters in the 
book apply to people with diabetes. This chapter addressed key diabetes-related care issues 
that need to be considered.
Significantly: The way people dies remains in the memory of those who live on. [Dame Cecily 
Saunders] [50].
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